|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0054658,
umls-concept:C0205210,
umls-concept:C0332464,
umls-concept:C0441655,
umls-concept:C0701185,
umls-concept:C1282910,
umls-concept:C1709630,
umls-concept:C1710493,
umls-concept:C1880355,
umls-concept:C1979775,
umls-concept:C2827424
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2005-4-1
|
|
pubmed:abstractText |
A series of fluoroglycosylated fluoroindolocarbazoles was examined with respect to their topoisomerase I activity, cytotoxicity, and selectivity. The lead clinical candidate from this series, BMS-250749, displays broad spectrum antitumor activity superior to CPT-11 against some preclinical xenograft models, including curative antitumor activity against Lewis lung carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
pubmed-author:BachandCarolC,
pubmed-author:BalasubramanianBalu NBN,
pubmed-author:BeaulieuFrancisF,
pubmed-author:EummerJeffrey TJT,
pubmed-author:FairchildCraig RCR,
pubmed-author:FrennessonDavid BDB,
pubmed-author:KramerRobertR,
pubmed-author:LangleyDavid RDR,
pubmed-author:LeeFrank YFY,
pubmed-author:LongByron HBH,
pubmed-author:MahlerMikaelM,
pubmed-author:MartelAlainA,
pubmed-author:NaiduB NarasimhuluBN,
pubmed-author:RoseWilliam CWC,
pubmed-author:RuedigerEdwardE,
pubmed-author:SaulnierMark GMG,
pubmed-author:SolomonCarolaC,
pubmed-author:St LaurentDenis RDR,
pubmed-author:StadnickLinda KLK,
pubmed-author:StoffanKaren MKM,
pubmed-author:VyasDolatrai MDM,
pubmed-author:WongHenryH,
pubmed-author:WrightJohn JJJ,
pubmed-author:ZimmermannKurtK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
7
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2258-61
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15801816-Animals,
pubmed-meshheading:15801816-Antineoplastic Agents,
pubmed-meshheading:15801816-Camptothecin,
pubmed-meshheading:15801816-Carbazoles,
pubmed-meshheading:15801816-Cell Line, Tumor,
pubmed-meshheading:15801816-Drug Evaluation, Preclinical,
pubmed-meshheading:15801816-Drug Resistance, Neoplasm,
pubmed-meshheading:15801816-Drug Screening Assays, Antitumor,
pubmed-meshheading:15801816-Glucosides,
pubmed-meshheading:15801816-Humans,
pubmed-meshheading:15801816-Indoles,
pubmed-meshheading:15801816-Mice,
pubmed-meshheading:15801816-Microsomes, Liver,
pubmed-meshheading:15801816-Topoisomerase I Inhibitors,
pubmed-meshheading:15801816-Transplantation, Heterologous
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11.
|
|
pubmed:affiliation |
The Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, Connecticut 06492, USA. Mark.Saulnier@bms.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
In Vitro
|
